CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
CARBON DIOXIDE, USP is an inhalation gas approved as a radiographic contrast agent for X-ray imaging procedures. It functions as a diagnostic tool to enhance visualization during medical imaging, leveraging carbon dioxide's radiopaque properties. This product serves a specialized role in diagnostic medicine rather than therapeutic intervention.
Product is at peak commercial maturity with moderate competitive pressure (30/100); team size and growth trajectory depend on diagnostic imaging procedure volume trends.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Martin Pharmaceuticals is hiring 1 role related to this product
Working on CARBON DIOXIDE, USP positions professionals in a niche diagnostic imaging space with stable but limited growth; career visibility is constrained by low job posting volume (0 linked positions) and narrow market segment. Success depends on expertise in regulatory compliance, diagnostic procedure protocols, and specialized sales channels rather than broad commercial scale.